GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of Jun. 08, 2024)


View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, SciClone Pharmaceuticals (Holdings)'s Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of SciClone Pharmaceuticals (Holdings)'s Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals (Holdings)'s Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SciClone Pharmaceuticals (Holdings)'s Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals (Holdings)'s Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals (Holdings)'s Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.


SciClone Pharmaceuticals (Holdings)  (HKSE:06600) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

SciClone Pharmaceuticals (Holdings) Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Comparable Companies
HKSE:00460 HKSE:02877 HKSE:01558 HKSE:01349 HKSE:01681 HKSE:03613 HKSE:06896 HKSE:02348 HKSE:01061 HKSE:02552 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN
Website
https://www.sciclone.com
SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.
Executives
Ubs Group Ag 2201 Interest of corporation controlled by you
Zhao Hong 2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang 2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited 2501 Other
Ascendent Capital Partners Ii Gp Limited 2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p. 2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p. 2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited 2101 Beneficial owner
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Bank Of China Limited 2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited 2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines